{
    "name": "thyrotropin alfa",
    "comment": "Rx",
    "other_names": [
        "Thyrogen"
    ],
    "classes": [
        "Diagnostics",
        "Endocrine"
    ],
    "source": "https://reference.medscape.com/drug/thyrogen-thyrotropin-alfa-342738",
    "pregnancy": {
        "common": [
            "Drug may be used in combination with radioiodine (RAI); if drug is administered with RAI, combination regimen is contraindicated in pregnant women because fetal exposure to RAI can lead to neonatal hypothyroidism, which in some cases is severe and irreversible; refer to RAI prescribing information for more information on use during pregnancy",
            "Available data from case reports and postmarketing experience with use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes; animal reproduction studies have not been conducted with drug"
        ],
        "specific": [
            {
                "type": "Reproductive potential",
                "description": [
                    "If drug is administered with RAI, the information for RAI regarding pregnancy testing, contraception, and infertility also applies to combination regimen; refer to RAI prescribing information for additional information"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "The concomitant use of drug and therapeutic radioiodine (RAI) is contraindicated in lactating women because RAI concentrates in breast tissue and increases risk of radiation breast toxicity (refer to therapeutic RAI Prescribing Information).",
            "If drug is administered with RAI for diagnostic use, discontinue breastfeeding after RAI administration because of potential for serious adverse reactions from RAI in breastfed infant (refer to diagnostic RAI Prescribing Information)",
            "If drug is not administered with RAI, developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for drug and any potential adverse effects on breastfed child from drug or from underlying maternal condition",
            "There are no available data on presence of thyrotropin alfa in human milk, effects on breastfed infant, or on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Warnings and precautions of radioiodine (RAI) apply if added in combination regimen; see warnings and precautions for RAI when used in combination",
                "Known to cause a transient (over 7 to 14 days) but significant rise in serum thyroid hormone concentration when given to patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases",
                "Sudden, rapid and painful tumor enlargement reported",
                "CHF, hypopituitarism, concurrent use of corticosteroids",
                "Anaphylactic reaction may occur after repeated use of thyrotropin",
                "Radioiodine testing 24 hr after final thyrotropin dose",
                "Reports of death within 24 hr after administration; patients for whom thyrotropin-induced hyperthyroidism could have serious consequences (eg, heart disease, extensive metastatic disease), consider hospitalization for administration and postadministration observation",
                "Reports of neurologic events, including acute hemiplegia or hemiparesis, occurring 1-3 days after administration to patients with CNS metastases; these events associated with sudden rapid tumor enlargement",
                "Postmarketing reports of stroke or unilateral weakness occurring within 72 hr (range 20 minutes to 3 days) of administration to women without known CNS metastases",
                "Tumor enlargement that is sudden, rapid and painful reported within 12-48 hr of administration; symptoms include dyspnea, stridor, or dysphonia; rapid clinical improvement occurred following glucocorticoid therapy (consider pretreatment with glucocorticoids if local tumor expansion may compromise vital anatomic structures)",
                "Use caution in patients with known history of heart disease"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "11"
        },
        {
            "name": "Headache",
            "percent": "6"
        },
        {
            "name": "Fatigue",
            "percent": "2"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Dizziness",
            "percent": "2"
        },
        {
            "name": "Asthenia",
            "percent": "1"
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "Erythema",
            "percent": null
        },
        {
            "name": "Bruising",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        }
    ]
}